<div id="readability-page-1"><p>Lake Street analyst Chad Messer maintained a Buy rating on OS Therapies Incorporated today and set a price target of $17.00.</p><h3>Claim 50% Off TipRanks Premium and Invest with Confidence </h3><ul><li>Unlock  hedge-fund level data  and  powerful investing tools  designed to help you make smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  so your portfolio is always positioned for maximum potential</li></ul> <p>Messer covers the Healthcare sector, focusing on stocks such as Coya Therapeutics, Inc., OS Therapies Incorporated, and Oncolytics Biotech. According to TipRanks, Messer has an average return of <span>-0.6%</span> and a 37.09% success rate on recommended stocks. </p> <p>OS Therapies Incorporated has an analyst consensus of Moderate Buy, with a price target consensus of $11.50.</p></div>

OSTX

<p>Lake Street analyst Chad Messer maintains a Buy rating for OS Therapies Incorporated, setting a price target of $17.00. The analyst has an average return of -0.6% and a 37.09% success rate. OS Therapies has a Moderate Buy consensus with a price target of $11.50.</p>

Lake Street Sticks to Their Buy Rating for OS Therapies Incorporated (OSTX)